{"id":"mycobacterium-w-immunotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mycobacterium w contains immunogenic mycobacterial antigens that activate pattern recognition receptors and dendritic cells, promoting Th1 and CD8+ T cell responses. This approach aims to boost the body's own immune system to recognize and eliminate cancer cells, potentially synergizing with checkpoint inhibitors or serving as a standalone immunotherapeutic agent.","oneSentence":"Mycobacterium w is a heat-killed mycobacterial immunotherapy that stimulates innate and adaptive immune responses to enhance anti-tumor immunity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:50:16.024Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (TB) as adjunctive immunotherapy"},{"name":"Advanced malignancies (under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT00694915","phase":"PHASE2","title":"Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder","status":"COMPLETED","sponsor":"Cadila Pharnmaceuticals","startDate":"2008-08-28","conditions":"Bladder Cancer","enrollment":122},{"nctId":"NCT00810849","phase":"PHASE3","title":"A Trial of Adjunctive Prednisolone and Mycobacterium w Immunotherapy in Tuberculous Pericarditis","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2008-12","conditions":"Tuberculous Pericarditis","enrollment":1400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Immuvac"],"phase":"phase_3","status":"active","brandName":"Mycobacterium w immunotherapy","genericName":"Mycobacterium w immunotherapy","companyName":"University of Cape Town","companyId":"university-of-cape-town","modality":"Biologic","firstApprovalDate":"","aiSummary":"Mycobacterium w is a heat-killed mycobacterial immunotherapy that stimulates innate and adaptive immune responses to enhance anti-tumor immunity. Used for Tuberculosis (TB) as adjunctive immunotherapy, Advanced malignancies (under investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}